A new generation of carbohydrate-based therapeutics: Recombinant mucin-type fusion proteins as versatile inhibitors of protein - Carbohydrate interactions

Expert Opinion on Drug Discovery

Volumn 1, Issue 2, 2006, Pages 161-178

  Gustafsson, Anki ^a   Holgersson, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

carbohydrate based inhibitor; glycoengineering; mucins; protein carbohydrate interaction; recombinant protein

Indexed keywords

EID: 36148929103     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.2.161     Document Type: Review

References (132)

1. COOK-MILLS JM, DEEM TL: Active participation of endothelial cells in inflammation. J. Leukoc. Biol. (2005) 77(4):487-495.
2. LIU Y, SHAW SK, MA S, YANG L, LUSCINSKAS FW, PARKOS CA: Regulation of leukocyte transmigration: cell surface interactions and signaling events. J. Immunol. (2004) 172(1):7-13.
3. VON ANDRIAN UH, MACKAY CR: T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. (2000) 343(14):1020-1034.
4. ROSEN SD: Ligands for L-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. (2004) 22:129-156.
5. SALMI M, JALKANEN S: Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol. Rev. (2005) 206:100-113.
6. YEH JC, HIRAOKA N, PETRYNIAK B et al.: Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N- acetylglucosaminyltransferase. Cell (2001) 105(7):957-969.
7. KAWASHIMA H, PETRYNIAK B, HIRAOKA N et al.: N-acetylglucosamine-6-O- sulfotransferases 1 and 2 cooperatively control lymphocyte homing through L-selectin ligand biosynthesis in high endothelial venules. Nat. Immunol. (2005) 6(11):1096-1104.
8. HIRAOKA N, PETRYNIAK B, NAKAYAMA J et al.: A novel, high endothelial venule-specific sulfotransferase expresses 6-sulfo sialyl Lewis(x), an L-selectin ligand displayed by CD34. Immunity (1999) 11(1):79-89.
9. POUYANI T, SEED B: PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus. Cell (1995) 83(2):333-343.
10. SAKO D, COMESS KM, BARONE KM, CAMPHAUSEN RT, CUMMING DA, SHAW GD: A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell (1995) 83(2):323-331.
11. SAKO D, CHANG XJ, BARONE KM et al.: Expression cloning of a functional glycoprotein ligand for P-selectin. Cell (1993) 75(6):1179-1186.
12. WALZ G, ARUFFO A, KOLANUS W, BEVILACQUA M, SEED B: Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science (1990) 250(4984):1132-1135.
13. ASA D, RAYCROFT L, MA L et al.: The P-selectin glycoprotein ligand functions as a common human leukocyte ligand for P- and E-selectins. J. Biol. Chem. (1995) 270(19):11662-11670.
14. WILKINS PP, MCEVER RP, CUMMINGS RD: Structures of the O-glycans on P-selectin glycoprotein ligand-1 from HL-60 cells. J. Biol. Chem. (1996) 271(31):18732-18742.
15. NIEMELA R, NATUNEN J, MAJURI ML et al.: Complementary acceptor and site specificities of Fuc-TIV and Fuc-TVII allow effective biosynthesis of sialyl-TriLex and related polylactosamines present on glycoprotein counterreceptors of selectins. J. Biol. Chem. (1998) 273(7):4021-4026.
16. HOMEISTER JW, THALL AD, PETRYNIAK B et al.: The ?(1,3)- fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. Immunity (2001) 15(1):115-126.
17. SMITHSON G, ROGERS CE, SMITH PL et al.: Fuc-TVII is required for T helper 1 and T cytotoxic 1 lymphocyte selectin ligand expression and recruitment in inflammation, and together with Fuc-TIV regulates naive T cell trafficking to lymph nodes. J. Exp. Med. (2001) 194(5):601-614.
18. WAGERS AJ, WATERS CM, STOOLMAN LM, KANSAS GS: Interleukin 12 and interleukin 4 control T cell adhesion to endothelial selectins through opposite effects on 1, 3-fucosyltransferase VII gene expression. J. Exp. Med. (1998) 188(12):2225-2231.
19. DUBE DH, BERTOZZI CR: Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. (2005) 4(6):477-488.
20. MAGNANI JL, STEPLEWSKI Z, KOPROWSKI H, GINSBURG V: Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. (1983) 43(11):5489-5492.
21. METZGAR RS, RODRIGUEZ N, FINN OJ et al.: Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc. Natl. Acad. Sci. USA (1984) 81(16):5242-5246.
22. KLUG TL, BAST RC JR, NILOFF JM, KNAPP RC, ZURAWSKI VR Jr: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. (1984) 44(3):1048-1053.
23. BAST RC Jr, FEENEY M, LAZARUS H, NADLER LM, COLVIN RB, KNAPP RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. (1981) 68(5):1331-1337.
24. PATERSON AJ, SCHLOM J, SEARS HF, BENNETT J, COLCHER D: A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. Int. J. Cancer (1986) 37(5):659-666.
25. HAKOMORI S: Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. (2001) 491:369-402.
26. DENNIS JW, LAFERTE S, WAGHORNE C, BREITMAN ML, KERBEL RS: ?1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (1987) 236(4801):582-585.
27. HOLLINGSWORTH MA, SWANSON BJ: Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer (2004) 4(1):45-60.
28. LIVINGSTON PO, ZHANG S, LLOYD KO: Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol. Immunother. (1997) 45(1):1-9.
29. LIVINGSTON PO, RAGUPATHI G: Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol. Immunother. (1997) 45(1):10-19.
30. MOINGEON P: Cancer vaccines. Vaccine (2001) 19(11-12):1305-1326.
31. SLOVIN SF, KEDING SJ, RAGUPATHI G: Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. (2005) 83(4):418-428.
32. ADA G, ISAACS D: Carbohydrate-protein conjugate vaccines. Clin. Microbiol. Infect. (2003) 9(2):79-85.
33. XU Y, SETTE A, SIDNEY J, GENDLER SJ, FRANCO A: Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol. Cell Biol. (2005) 83(4):440-448.
34. KUDRYASHOV V, GLUNZ PW, WILLIAMS LJ, HINTERMANN S, DANISHEFSKY SJ, LLOYD KO: Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc. Natl. Acad. Sci. USA (2001) 98(6):3264-3269.
35. GILEWSKI T, RAGUPATHI G, BHUTA S et al.: Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a Phase I trial. Proc. Natl. Acad. Sci. USA (2001) 98(6):3270-3275.
36. FUSTER MM, BROWN JR, WANG L, ESKO JD: A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res. (2003) 63(11):2775-2781.
37. HORIMOTO T, KAWAOKA Y: Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. (2005) 3(8):591-600.
38. SUZUKI Y: Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol. Pharm. Bull. (2005) 28(3):399-408.
39. SHINYA K, EBINA M, YAMADA S, ONO M, KASAI N, KAWAOKA Y: Influenza virus receptors in the human airway. Avian and human flu viruses seem to target different regions of a patients respiratory tract. Nature (2006) 440:435-436.
40. WILHELMI I, ROMAN E, SANCHEZ-FAUQUIER A: Viruses causing gastroenteritis. Clin. Microbiol. Infect. (2003) 9(4):247-262.
41. CIARLET M, CRAWFORD SE, ESTES MK: Differential infection of polarized epithelial cell lines by sialic acid-dependent and sialic acid-independent rotavirus strains. J. Virol. (2001) 75(23):11834-11850.
42. HUTSON AM, ATMAR RL, MARCUS DM, ESTES MK: Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J. Virol. (2003) 77(1):405-415.
43. RUIZ-PALACIOS GM, PEREZ-SCHAEL I, VELAZQUEZ FR et al.: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. (2006) 354(1):11-22.
44. VESIKARI T, MATSON DO, DENNEHY P et al.: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. (2006) 354(1):23-33.
45. KONKEL ME, MONTEVILLE MR, RIVERA-AMILL V, JOENS LA: The pathogenesis of Campylobacter jejuni-mediated enteritis. Curr. Issues Intest. Microbiol. (2001) 2(2):55-71.
46. CLARKE SC, HAIGH RD, FREESTONE PP, WILLIAMS PH: Virulence of enteropathogenic Escherichia coli, a global pathogen. Clin. Microbiol. Rev. (2003) 16(3):365-378.
47. GAASTRA W, SVENNERHOLM AM: Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol. (1996) 4(11):444-452.
48. KARMALI MA: Infection by Shiga toxin-producing Escherichia coli: an overview. Mol. Biotechnol. (2004) 26(2):117-122.
49. CRAVIOTO A, TELLO A, VILLAFAN H, RUIZ J, DEL VEDOVO S, NEESER JR: Inhibition of localized adhesion of enteropathogenic Escherichia coli to HEp-2 cells by immunoglobulin and oligosaccharide fractions of human colostrum and breast milk. J. Infect. Dis. (1991) 163(6):1247-1255.
50. RUIZ-PALACIOS GM, CERVANTES LE, RAMOS P, CHAVEZ-MUNGUIA B, NEWBURG DS: Campylobacter jejuni binds intestinal H(O) antigen (Fuc α1, 2Gal Β1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J. Biol. Chem. (2003) 278(16):14112-14120.
51. MAHDAVI J, SONDEN B, HURTIG M et al.: Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science (2002) 297(5581):573-578.
52. ILVER D, ARNQVIST A, OGREN J et al.: Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science (1998) 279(5349):373-377.
53. BLASER MJ: The bacteria behind ulcers. Sci. Am. (1996) 274(2):104-107.
54. AEBISCHER T, SCHMITT A, WALDUCK AK, MEYER TF: Helicobacter pylori vaccine development: facing the challenge. Int. J. Med. Microbiol. (2005) 295(5):343-353.
55. WATKINS WM: The ABO blood group system: historical background. Transfus. Med. (2001) 11(4):243-265.
56. YAMAMOTO F: Review: ABO blood group system-ABH oligosaccharide antigens, anti-A and anti-B, A and B glycosyltransferases, and ABO genes. Immunohematol. (2004) 20(1):3-22.
57. GLEASON R, MURRAY J: Report from kidney transplant registry: analysis of variables in the function of human kidney transplants. Blood group compatibility and splenectomy. Transplantation (1967) 5:343-359.
58. HOLGERSSON J, GUSTAFSSON A, BREIMER ME: Characteristics of protein-carbohydrate interactions as a basis for developing novel carbohydrate-based antirejection therapies. Immunol. Cell Biol. (2005) 83(6):694-708.
59. MAAHEIMO H, RENKONEN R, TURUNEN JP, PENTTILA L, RENKONEN O: Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion. Evidence that multivalency enhances the saccharide binding to L-selectin. Eur. J. Biochem. (1995) 234(2):616-625.
60. IMBERTY A, MIKROS E, KOCA J, MOLLICONE R, ORIOL R, PEREZ S: Computer simulation of histo-blood group oligosaccharides: energy maps of all constituting disaccharides and potential energy surfaces of 14 ABH and Lewis carbohydrate antigens. Glycoconj. J. (1995) 12(3):331-349.
61. BOVIN NV: Polyacrylamide-based glycoconjugates as tools in glycobiology. Glycoconj. J. (1998) 15(5):431-446.
62. LOWE JB: Selectin ligands, leukocyte trafficking, and fucosyltransferase genes. Kidney Int. (1997) 51(5):1418-1426.
63. HOLGERSSON J, LOFLING J: Glycosyltransferases involved in type 1 chain and Lewis antigen biosynthesis exhibit glycan and core chain specificity. Glycobiology (2006) 16(7):584-593.
64. GERKEN TA, TEP C, RARICK J: Role of peptide sequence and neighboring residue glycosylation on the substrate specificity of the uridine 5α-diphosphate-α-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyl transferases T1 and T2: kinetic modeling of the porcine and canine submaxillary gland mucin tandem repeats. Biochemistry (2004) 43(30):9888-9900.
65. MAMMEN M, CHOI S, WHITESIDES G: Polyvalent interactions in biological systems:implications for design and use of multivalent ligands and inhibitors. Angew Chem. Int. Ed. (1998) 37:2754-2794.
66. LEE RT, LEE YC: Affinity enhancement by multivalent lectin-carbohydrate interaction. Glycoconj. J. (2000) 17(7-9):543-551.
67. DAM TK, ROY R, PAG D, BREWER CF: Thermodynamic binding parameters of individual epitopes of multivalent carbohydrates to Concanavalin A as determined by reverse isothermal titration microcalorimetry. Biochemistry (2002) 41:1359-1363.
68. LEE YC, TOWNSEND RR, HARDY MR et al.: Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J. Biol. Chem. (1983) 258(1):199-202.
69. RICE KG, WEISZ OA, BARTHEL T, LEE RT, LEE YC: Defined geometry of binding between triantennary glycopeptide and the asialoglycoprotein receptor of rat heptocytes. J. Biol. Chem. (1990) 265(30):18429-18434.
70. KÖ;HN M, BENITO JM, ORTIZMELLET C, LINDHORST TK, GARCÍA FERNÁNDEZ JM: Functional evaluation of carbohydrate-centred glycoclusters by enzyme-linked lectin assay: ligands for concanavalin A. ChemBioChem (2004) 5:771-777.
71. DUVERGER E, FRISON N, ROCHE A-C, MONSIGNY M: Carbohydrate-lectin interactions assessed by surface plasmon resonance. Biochimie (2003) 85:167-179.
72. SUN X-L, CUI W, HALLER C, CHAIKOF EL: Site-specific multivalent carbohydrate labeling of quantum dots and magnetic beads. ChemBioChem (2004) 5:1593-1596.
73. HUANG G-L, LIU T-C, LIU M-X, MEI X-Y: The application of quantum dots as fluorescent label to glycoarray. Anal. Biochem. (2005) 340:52-56.
74. HUANG C-Y, THAYER DA, CHANG AY et al.: Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc. Natl. Acad. Sci. USA (2006) 103(1):15-20.
75. STEVENS J, BLIXT O, TUMPEY TM, TAUBENBERGER JK, PAULSON JC, WILSON IA: Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science (2006) 312:404-410.
76. MANIMALA JC, ROACH TA, LI Z, GILDERSLEEVE JC: High-throughput carbohydrate microarray analysis of 24 lectins. Angew Chem. Int. Ed. (2006) 45:3607-3610.
77. EDEN CS, FRETER R, HAGBERG L et al.: Inhibition of experimental ascending urinary tract infection by an epithelial cell-surface receptor analogue. Nature (1982) 298(5874):560-562.
78. IDANPAAN-HEIKKILA I, SIMON PM, ZOPF D et al.: Oligosaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia. J. Infect. Dis. (1997) 176(3):704-712.
79. MULLIGAN MS, PAULSON JC, DE FREES S, ZHENG ZL, LOWE JB, WARD PA: Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature (1993) 364(6433):149-151.
80. SILVER MJ, SUTTON JM, HOOK S et al.: Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation (1995) 92(3):492-499.
81. FRIEDRICH M, BOCK D, PHILIPP S et al.: Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch. Dermatol. Res. (2006) 297(8):345-351.
82. BEEH KM, BEIER J, MEYER M, BUHL R, ZAHLTEN R, WOLFF G: Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm. Pharmacol. Ther. (2006) 19(4):233-241.
83. KERR KM, AUGER WR, MARSH JJ et al.: The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am. J. Respir. Crit. Care Med. (2000) 162(1):14-20.
84. UKKONEN P, VARIS K, JERNFORS M et al.: Treatment of acute otitis media with an antiadhesive oligosaccharide: a randomised, double-blind, placebo-controlled trial. Lancet (2000) 356(9239):1398-1402.
85. MULVEY GL, MARCATO P, KITOV PI, SADOWSKA J, BUNDLE DR, ARMSTRONG GD: Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J. Infect. Dis. (2003) 187(4):640-649.
86. NISHIKAWA K, MATSUOKA K, KITA E et al.: A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. USA (2002) 99(11):7669-7674.
87. LOFLING JC, HAUZENBERGER E, HOLGERSSON J: Absorption of anti-blood group A antibodies on P-selectin glycoprotein ligand-1/immunoglobulin chimeras carrying blood group A determinants: core saccharide chain specificity of the Se and H gene encoded α1,2 fucosyltransferases in different host cells. Glycobiology (2002) 12(3):173-182.
88. LIU J, GUSTAFSSON A, BREIMER ME, KUSSAK A, HOLGERSSON J: Anti-pig antibody adsorption efficacy of {?}-Gal carrying recombinant P-selectin glycoprotein ligand-1/immunoglobulin chimeras increases with core 2 {?}1, 6-N-acetylglucosaminyltransferase expression. Glycobiology (2005) 15(6):571-583.
89. LIU J, WEINTRAUB A, HOLGERSSON J: Multivalent Galα1,3Gal- substitution makes recombinant mucin-immunoglobulins efficient absorbers of anti-pig antibodies. Xenotransplantation (2003) 10(2):149-163.
90. LIU J, QIAN Y, HOLGERSSON J: Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Gal?1,3Gal epitope. Transplantation (1997) 63(11):1673-1682.
91. RYDBERG L, BENGTSSON A, SAMUELSSON O, NILSSON K, BREIMER ME: In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose. Transpl. Int. (2005) 17(11):666-672.
92. TYDEN G, KUMLIEN G, GENBERG H, SANDBERG J, LUNDGREN T, FEHRMAN I: ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am. J. Transplant. (2005) 5(1):145-148.
93. RYDBERG L, BREIMER ME, HOLGERSSON J et al.: Characterisation of the anti-A antibody response following an ABO incompatible (A2 to O) kidney transplantation. Mol. Immunol. (1992) 29(4):547-560.
94. IMBERTY A, MOLLICONE R, MIKROS E, CARRUPT PA, PEREZ S, ORIOL R: How do antibodies and lectins recognize histo-blood group antigens? A 3D-QSAR study by comparative molecular field analysis (CoMFA). Bioorg. Med. Chem. (1996) 4(11):1979-1988.
95. MANEZ R, DOMENECH N, CENTENO A et al.: Failure to deplete anti-Gal?1-3Gal antibodies after pig-to-baboon organ xenotransplantation by immunoaffinity columns containing multiple Galα1-3Gal oligosaccharides. Xenotransplantation (2004) 11(5):408-415.
96. TANIGUCHI S, NEETHLING FA, KORCHAGINA EY T et al.: In vivo immunoadsorption of antipig antibodies in baboons using a specific Gal(α)1-3Gal column. Transplantation (1996) 62(10):1379-1384.
97. XU Y, LORF T, SABLINSKI T et al.: Removal of anti-porcine natural antibodies from human and nonhuman primate plasma in vitro and in vivo by a Gal?1-3Gal?1-4?Glc-X immunoaffinity column. Transplantation (1998) 65(2):172-179.
98. KAROOR S, MOLINA J, BUCHMANN CR, COLTON C, LOGAN JS, HENDERSON LW: Immunoaffinity removal of xenoreactive antibodies using modified dialysis or microfiltration membranes. Biotechnol. Bioeng. (2003) 81(2):134-148.
99. WERNER RG, NOE W, KOPP K, SCHLUTER M: Appropriate mammalian expression systems for biopharmaceuticals. Arzneimittelforschung (1998) 48(8):870-880.
100. VERMA R, BOLETI E, GEORGE AJ: Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods (1998) 216(1-2):165-181.
101. PAHLSSON P, BLACKALL DP, UGORSKI M, CZERWINSKI M, SPITALNIK SL: Biochemical characterization of the O-glycans on recombinant glycophorin A expressed in Chinese hamster ovary cells. Glycoconj. J. (1994) 11(1):43-50.
102. SASAKI H, BOTHNER B, DELL A, FUKUDA M: Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem. (1987) 262(25):12059-12076.
103. KUMAR R, CAMPHAUSEN RT, SULLIVAN FX, CUMMING DA: Core2 α-1,6-N-acetylglucosaminyltransferase enzyme activity is critical for P-selectin glycoprotein ligand-1 binding to P-selectin. Blood (1996) 88(10):3872-3879.
104. BIERHUIZEN MF, MAEMURA K, FUKUDA M: Expression of a differentiation antigen and poly-N-acetyllactosaminyl O-glycans directed by a cloned core 2 beta-1,6-N-acetylglucosaminyltransferase. J. Biol. Chem. (1994) 269(6):4473-4479.
105. LINK T, BACKSTROM M, GRAHAM R et al.: Bioprocess development for the production of a recombinant MUC1 fusion protein expressed by CHO-K1 cells in protein-free medium. J. Biotechnol. (2004) 110(1):51-62.
106. GAWLITZEK M, RYLL T, LOFGREN J, SLIWKOWSKI MB: Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms. Biotechnol. Bioeng. (2000) 68(6):637-646.
107. FORNO G, BOLLATI FOGOLIN M, OGGERO M et al.: N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. Eur. J. Biochem. (2004) 271(5):907-919.
108. GOLDMAN MH, JAMES DC, RENDALL M, ISON AP, HOARE M, BULL AT: Monitoring recombinant human interferon-αN-glycosylation during perfused fluidized-bed and stirred-tank batch culture of CHO cells. Biotechnol. Bioeng. (1998) 60(5):596-607.
109. DIAMOND LE, BYRNE GW, SCHWARZ A, DAVIS TA, ADAMS DH, LOGAN JS: Analysis of the control of the anti-gal immune response in a non-human primate by galactose α1-3 galactose trisaccharide-polyethylene glycol conjugate. Transplantation (2002) 73(11):1780-1787.
110. TURNBULL WB, KALOVIDOURIS SA, STODDART JF: Large oligosaccharide-based glycodendrimers. Chem. Eur. J. (2002) 8:2988-3000.
111. FULTON DA, STODDART JF: Neoglycoconjugates based on cyclodextrins and calixarenes. Bioconjug. Chem. (2001) 12(5):655-672.
112. DOORES KJ, GAMBLIN DP, DAVIS BG: Exploring and exploiting the therapeutic potential of glycoconjugates. Chemistry (2006) 12(3):656-665.
113. GAREGG PJ: Synthesis and reactions of glycosides. Adv. Carbohydr. Chem. Biochem. (2004) 59:69-134.
114. HANSON S, BEST M, BRYAN MC, WONG CH: Chemoenzymatic synthesis of oligosaccharides and glycoproteins. Trends Biochem. Sci. (2004) 29(12):656-663.
115. SEARS P, WONG CH: Toward automated synthesis of oligosaccharides and glycoproteins. Science (2001) 291(5512):2344-2350.
116. SEEBERGER PH, WERZ DB: Automated synthesis of oligosaccharides as a basis for drug discovery. Nat. Rev. Drug Discov. (2005) 4(9):761-763.
117. PLANTE OJ, PALMACCI ER, SEEBERGER PH: Automated solid-phase synthesis of oligosaccharides. Science (2001) 291(5508):1523-1527.
118. KIMURA H, SHINYA N, NISHIHARA S, KANEKO M, IRIMURA T, NARIMATSU H: Distinct substrate specificities of five human α-1,3-fucosyltransferases for in vivo synthesis of the sialyl Lewis x and Lewis x epitopes. Biochem. Biophys. Res. Commun. (1997) 237(1):131-137.
119. GRABENHORST E, NIMTZ M, COSTA J, CONRADT HS: In vivo specificity of human α1,3/4-fucosyltransferases III-VII in the biosynthesis of Lewis X and Sialyl Lewis X motifs on complex-type N-glycans. Coexpression studies from bhk-21 cells together with human α-trace protein. J. Biol. Chem. (1998) 273(47):30985-30994.
120. BENNETT EP, HASSAN H, MANDEL U et al.: Cloning of a human UDP-N-acetyl-α-D-Galactosamine:polypep tide N- acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat. J. Biol. Chem. (1998) 273(46):30472-30481.
121. LI F, WILKINS PP, CRAWLEY S, WEINSTEIN J, CUMMINGS RD, MCEVER RP: Posttranslational modifications of recombinant P-selectin glycoprotein ligand-1 required for binding to P- and E-selectin. J. Biol. Chem. (1996) 271(6):3255-3264.
122. OLSON FJ, BACKSTROM M, KARLSSON H, BURCHELL J, HANSON GC: A MUC1 tandem repeat reporter protein produced in CHO-K1 cells has sialylated core 1 O-glycans and becomes densely glycosylated if coexpressed with polypeptide-GalNAc-T4 transferase. Glycobiology (2005) 15(2):177-191.
123. BROCKHAUSEN I, YANG J, LEHOTAY M, OGATA S, ITZKOWITZ S: Pathways of mucin O-glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancer-associated Sialyl-tn antigen expression. Biol. Chem. (2001) 382(2):219-232.
124. WHITEHOUSE C, BURCHELL J, GSCHMEISSNER S, BROCKHAUSEN I, LLOYD KO, TAYLOR-PAPADIMITRIOU J: A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J. Cell Biol. (1997) 137(6):1229-1241.
125. YANO H, YAMAMOTO-HINO M, ABE M et al.: Distinct functional units of the Golgi complex in Drosophila cells. Proc. Natl. Acad. Sci. USA (2005) 102(38):13467-13472.
126. FERNANDEZ-RODRIGUEZ J, DWIR O, ALON R, HANSSON GC: Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions. Glycoconj. J. (2001) 18(11-12):925-930.
127. SCHELLEKENS H: Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. (2002) 1(6):457-462.
128. BORREBAECK CK, MALMBORG AC, OHLIN M: Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol. Today (1993) 14(10):477-479.
129. CHENU S, GREGOIRE A, MALYKH Y et al.: Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy. Biochim. Biophys. Acta (2003) 1622(2):133-144.
130. KOURY MJ: Sugar coating extends half-lives and improves effectiveness of cytokine hormones. Trends Biotechnol. (2003) 21(11):462-464.
131. WEIKERT S, PAPAC D, BRIGGS J et al.: Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat. Biotechnol. (1999) 17(11):1116-1121.
132. http://www.clinicaltrials.gov Provides regularly updated information about federally and privately supported clinical research in human volunteers(2006).